La tech au service de la santé féminine lève 60 millions - Aspivix

Untitled-design-3

La tech au service de la santé féminine lève 60 millions

December 8, 2021

Share this story:

More from our blog

X-HEALTHshow_Aspivix_cover-1

Aspivix CEO Mathieu Horras Discusses How Much IUD Inserstion Can Hurt Less on X-Health.show

Aspivix featured in forbes

Aspivix Featured in Forbes France Following Top 10 Placement at Inaugural MedFemTech Congress

Contraception Journal linkedin (3)

ASPIVIX Announces That Contraception, an International Reproductive Health Journal, Has Published First-In-Women Results Using Novel Cervical Stabilizer In IUD Procedures

Aspivix-FDA-510k-FDA-Approved

Aspivix receives U.S. FDA 510(k) Clearance for Carevix™, Their Novel Cervical Stabilizer

Femtech World Blog Cover

Aspivix mentioned in Femtech World about Serie A

Closed Series A+ funding round

ASPIVIX – Manufacturer of non-traumatic medical devices for gynecology – closes $5M Series A+ Funding Round and receives a large EUREKA-EUROSTARS grant co-funded by Innosuisse, the Swiss Innovation Agency.

Female clinician shaking hand of young happy Hispanic patient sitting on couch in medical office after ultrasound examination

10 Simple Steps Gynecologists Can Take to Enhance Patient Experience

Woman stressed about contraceptive myths

5 Common Myths About Contraceptives

aspivix_MG_0208

A modern approach to women’s healthcare

aspivix_MG_0243

Clinical data show significantly lower IUD procedural pain and bleeding rates with Aspivix’s novel suction-based cervical device